国际皮肤性病学杂志    2001 27 (6): 329-332   ISSN: 2096-5540  CN: 32-1880/R   沙利度胺近三年来研究进展 王雨娟综述1, 郑家润审校2 1. 中国医学科学院皮肤病研究所; 2. 中国协和医科大学皮肤病研究所 收稿日期 null  修回日期 null  网络版发布日期 null 参考文献  [1] Stirling DI.Thalidomide and its impact in dermatology.Semin Cutan MedSurg,1998,17(4):231-242. [2] Dunzendorfer S,Herold M,Wiedermann CJ.Inducer-specific bidirectionalregulation of endothelial IL-8 production by Thalidomide.Immunopharmacology,1999,43:59-64. [3] Meierhefer C,Dunzendorfer S,Wiedermann CJ.Protein kinase C-dependenteffects on leukocyte migration of Thalidomide.J Infect Dis,1999,180(1):216-219. [4] Corral LG,Kaplan G.Immunomodulation by Thalidomide and Thalidomideanalogues.Ann Rheum Dis,1999,58(Suppl 1):I107-I113. [5] Corxal LG,Haslett PA J,Muller GW,et al.Differential cytokine molulationand T cell activation by two distinct classes of Thalidomide analogues thatare potent inhibitors of TNF-α.J Immunol,1999,163(1):380-386. [6] Haslett PA,Klausner JD,Makonkawkeyoon S,et al.Thalidomide stimulatesT cell responses and IL-12 production in HIV-infected patients.AIDS ResHum Retroviruses,1999,15(13):1169-1179. [7] Teo SK,Sabourin PJ,O' Brien K,et al.Metabolism of Thalidomide inhuman microsomes,cloned human cytochrome P-450 isozymes,andHansen's disease patients.J Biochem Mol Toxicol,2000,14(3):140-147. [8] Joussen AM,G erman T,Kirchhof B.Effect of Thalidomide and strueturallyrelated compounds on corneal angiogenesis is comparable to THeir terato-logical potency.Graefes Arch Clin Exp Ophthalmol,1999,237(12):952-961. [9] Stephens TD,Bunde C J,Fillmore BJ.Mechanism of action in Thalidomideteratogenesis.Biochem Phamacol,2000,59:1489-1499. [10] Paman T,Wiley MJ,Wells PG.Free radical-mediated oxidative DNA dam-age in the mechanism of Thalidomide teratogenieity.Nat Med,1999,5(5):582-585. [11] Thiele A,Thormann M,Hofman H J,et al.A possible role of N-cadherin inThalidomide teratogenicity.Life Sci,2000,67(4):457-461. [12] Ordi-Ros.J,Cortes F,Cucurull E,et al.Thalidomide in The treatment ofcutaneous lupus refractory to conventional Therapy.J Rheumatol,2000,27(16):1429-1433. [13] Kyriakis KP,Kontochristopoulos GJ,Panteleos DN.Experience with low dose thalidomide Therapy in chronic discoid lupus erythematosus.Int J Dermatol,2000,39(3):218-222. [14] Walchner M,Meurer M,Plewig G,et al.Clinical and immunologic parame-ters during thalidomide treatment of lupus erythematosus.Int J Dermatol,2000,39(5):383-388. [15] Browne PV,Weisdorf DJ,DeFor T,et al.Response to thalidomide therapyin refractory chronic graft-versus-host disease.Bone Marrow Transplant,2000,26 (8):865-869. [16] Kaplan G,Schambelan M,Gottlieb M,et al.Thalidomide reverses cachexia in HIV-wasting syndrme.5th Conference on Retroviruses and Opportunis tic Infections.Chicago,IL,1998,Abstract 476. [17] Bekker LG,Haslett P,Maartens G,et al.Thalidomide-induced antigen-specific immune stimulation in patients wiTH human immunodeficiency virus type 1 and tuberculosis.J Infect Dis,2000,181(3):954-965. [18] G uckian M,Dransfield I,Hay P,et al.Thalidomide analogue CC-3052 re-duces HIV + neutrophil apoptosis in vitro.Clin Exp Immunol,2000,121(3):472-479. [19] Juffermans NP,Verbon A,Olszyna DP,et al.Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5on CD4+ T cells in hurmans.J Infect Dis,2000,181(5):1813-1816. [20] Jacobson JM,Spritzler J,Fox L,et al.Thalidomide for the treament ofesophageal aphthous ulcers in patients with human immunodeficiency virusinfection.National Institute of Allergy and Infectious Disease AIDS ClinicalTrials Group.J Infect Dis,1999,180(1):61-67. [21] Ridoux O,Drancourt M.Lack of in vitro antimicrosporidian activity ofthalidomide.Antimicrob Agents Chemother,1999,43(9):2305-2316. [22] Oliver SJ,Freeman SL,Corral LG,et al.Thalidomide analogue CC1069 in-hibits development of rat adjuvant arthritis.Clin Exp Immunol,1999,118(2):315-321. [23] Keesal N,Wasserman MJ,Bookman A,et al.Thalidomide in the treatmentof refractory rheumatoid arthritis.J Rheumatol,1999,26(11):2344-2347. [24] Marriott JB,Westby M,Cookson S,et al.CC-3052:a water-soluble analogof Thalidomide and potent inhibitor of activation-induced TNF-α produc-tion.J Immunol,1998,161 (8):4236-4243. 通讯作者: